Objective: Lung adenocarcinoma (LUAD) is a prominent contributor to
global cancer mortality, characterized by constrained prognosis. This study aimed
to develop a novel prognostic indicator, the Cell Death Index (CDI), utilizing
twelve programmed cell death (PCD) pattern genes, to predict the immune
infiltration and prognosis in LUAD patients. Methods: We collected
PCD-related genes and identified prognostic PCD genes in the Cancer Genome Atlas
(TCGA)-LUAD dataset, and made rigorous validation in the Clinical Proteomic Tumor
Analysis Consortium (CPTAC)-LUAD cohorts. CDI was calculated using a
multivariable Cox regression model. Functional enrichment and tumor
microenvironment were evaluated. Drug sensitivity prediction and nomogram
development were performed to assess CDI’s potential value. Results: The
results revealed 10 PCD genes (ERO1A, CDK5R1, TRIM6,
DNASE2B, ITPRIP, MRGPRX2, FGA,
NDUFA13, NLRP2, and CD68) significantly associated
with LUAD prognosis. The CDI was constructed and showed high accuracy in
predicting patient survival with C-index values of 0.801 and 0.794 in the
prognosis cohort and validation cohort, respectively. CDI is also indicative of
variations in biological functions, tumor microenvironment, and immune cell
infiltration including neutrophils, activated mast cells, activated dendritic
cells, M0 macrophages, resting natural killer cells,
-This study introduces a novel prognostic indicator named the Cell Death Index (CDI), based on programmed cell death genes, for predicting immune infiltration and prognosis in LUAD patients.
-CDI exhibits remarkable accuracy in predicting patient survival, with C-index values of 0.801 and 0.794 in the prognosis cohort and validation cohort, respectively.
-The CDI, comprising ten programmed cell death genes, demonstrates a significant association with LUAD prognosis and offers insights into tumor biology, tumor microenvironment, and immune cell infiltration.